Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Apelin-13

APJ Receptor Agonist Tridecapeptide

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

Apelin-13 is an endogenous APJ (apelin receptor) agonist with real human data, but only from small acute infusion studies. In the Edinburgh/Circulation work (Barnes, Japp, Newby and colleagues), short intravenous infusions of [Pyr1]apelin-13 raised cardiac index and lowered systemic vascular resistance and blood pressure in chronic heart failure patients and healthy volunteers, an acute hemodynamic signal rather than a chronic outcome benefit. Its plasma half-life is only a few minutes, it has no approved product, and analog programs (Novartis CLR325, BMS-986224, AMG 986) did not advance, so an honest grade for the supported acute-hemodynamic use is 2.

FDA
No approved product; investigational only. Native Apelin-13 has been used solely in short-term human research infusions, and analog programs (Novartis CLR325, BMS-986224, AMG 986) did not advance to approval.
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

No approved product and no chronic human safety data; effects are acute and short-lived, and gray-market material is sold as a research chemical of unverified purity.

Talk to a clinician before taking this, particularly if you have a heart condition. The Atlas can tell you what has been studied about Apelin-13. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

An endogenous APJ-receptor peptide that is inotropic, vasodilatory, anti-fibrotic, and promotes mitochondrial biogenesis. Plasma levels fall with heart failure and aging.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Heart failure research
  • Mitochondrial biogenesis

How it is supposed to work

Apelin-13 is a short, active form of the neuropeptide apelin, the natural partner of the APJ receptor (a relative of the angiotensin receptor). It supports the heart as a positive inotrope, relaxes blood vessels, improves insulin sensitivity, and in the brain is neuroprotective and pro-angiogenic. The apelin-APJ system is an active cardiovascular and metabolic drug target.

Apelin-13 is a thirteen-amino-acid fragment of the natural hormone apelin, the body’s ligand for the APJ receptor on heart and vessel cells. It is one of the most active forms of apelin, but its great weakness as a drug is built in: the body breaks it down in under five minutes. It is sold gray-market as a research peptide, not an approved drug.

Type
Fragment of apelin
Target
APJ receptor
Effect
Heart contraction, vasodilation
Best data
Preclinical heart failure
Half-life
Under 5 minutes
Approved
No

A Potent Heart Peptide That Vanishes In Minutes

Apelin-13 is a case where the biology is genuinely exciting, the drug target is taken seriously by major pharma, and the native peptide itself is still a poor medicine, all at once. Its effects are real and potent: it is among the strongest natural boosters of heart-muscle contraction, and in heart-failure models it restores pumping function and output while relaxing blood vessels and, unusually, without causing the harmful muscle thickening that limits other approaches. That profile has made the apelin system a serious target for heart failure, hypertension and metabolic disease. But native apelin-13 has a fatal flaw as a drug: it is degraded in well under five minutes, so its effects vanish almost as fast as they appear. The honest consequence is that the real therapeutic work is not on apelin-13 itself but on stabilized analogs and small-molecule drugs that hit the same receptor and last. Native apelin-13 remains essentially a research compound with no human therapeutic use, which makes its gray-market sale for heart and metabolic health doubly questionable: there is no human evidence behind it, and its half-life is so short that injecting the native peptide makes little pharmacological sense.

Safety in detail

  • As a vasoactive, cardioactive peptide, its effects on heart and vessels require careful study; broad-population safety is not established.
  • Its extremely short half-life is a practical obstacle.
  • It remains investigational, without an approved product.
  • Any consumer material would be gray-market and unverified.

Children and teenagers

Apelin-13 is a cardiovascularly active research peptide with no human trials, which makes it inappropriate for children. Pediatric heart conditions belong with pediatric cardiology, and the peptide’s potent cardiac activity makes unsupervised use especially unsuitable for minors. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Native apelin-13’s commercial life is small, sold as a research reagent and gray-market for cardiovascular, metabolic and exercise use. The real value of its biology lies in pharmaceutical development of stabilized analogs and small-molecule receptor drugs for heart failure and related diseases. It is a valuable target whose native peptide is the cheap but wrong version.

How we got here

Apelin was isolated in 1998 as the endogenous ligand for the orphan APJ receptor, a G-protein-coupled receptor identified in 1993 that shares partial homology with the angiotensin II receptor. Preproapelin is cleaved into several active fragments, with the 13-residue C-terminal peptide (apelin-13) and its pyroglutamylated form [Pyr1]apelin-13 dominating in the cardiovascular system. Cardiovascular interest drove human acute-infusion studies at Edinburgh and elsewhere and a wave of drug programs, including Novartis's cyclic analog CLR325 and small molecules such as BMS-986224 and AMG 986, that sought to overcome the native peptide's few-minute half-life; none reached approval. Today Apelin-13 has no approved product and circulates on the gray market as a research chemical labeled not for human consumption.

Apelin was discovered in 1998 as the body’s ligand for the APJ receptor, and apelin-13 was identified as one of its most active fragments. Strong preclinical cardiovascular data followed, showing potent heart-strengthening effects without muscle thickening, but its sub-five-minute half-life emerged as the key barrier to using the native peptide as a drug. Development shifted to stabilized analogs and small-molecule receptor drugs, while native apelin-13 appeared as a gray-market peptide.

  1. 1998Apelin is discovered as the ligand for the APJ receptor.
  2. 2000sApelin-13 is shown to be a potent heart-strengthening fragment.
  3. 2000s-2010sHeart-failure models show restored function without muscle thickening.
  4. ongoingDevelopment shifts to stabilized analogs and small-molecule drugs.
  5. recentNative apelin-13 appears as a gray-market peptide.

The numbers behind the grade

Type
Apelin (APJ ligand)
Action
Cardiac, metabolic, neuro
Half-life
Very short
Stage
Investigational
Approved
No
Use
Research

The people taking it

A promising cardiovascular and metabolic research peptide, part of an active drug-target system, but not a consumer compound.

Apelin-13’s gray-market users are people seeking cardiovascular or metabolic support, exercise-performance users and heart-health biohackers drawn by its strong cardiac biology. Its legitimate interest lies in cardiovascular drug development. The thread is a fascination with a potent heart peptide.

Studied in research for heart failure, insulin sensitivity and stroke neuroprotection via the apelin-APJ system; it has no approved consumer use.

Set against the alternatives

Against the engineered apelin analogs and small-molecule receptor drugs in pharmaceutical pipelines, native apelin-13 is the short-lived prototype, while the developable versions are built to last. Against other heart-strengthening drugs, apelin’s appeal is that it boosts contraction without the muscle thickening that limits some of them, an attractive clean profile, if a usable form can be made. And against other gray-market cardiovascular and metabolic peptides, it shares the pattern of strong biology outrunning human evidence. Its strength is a genuinely promising target; its weakness is that the native molecule is the wrong tool.

What we do not know

  • Whether the cardiac and metabolic benefits of apelin can be turned into a usable drug.
  • How to overcome its very rapid degradation.
  • Whether its neuroprotective effects matter in human stroke.

What could change

Stabilized analogsLonger-lasting apelin analogs are in development for heart failure.Small-molecule agonistsDrugs hitting the same receptor aim to last far longer.Metabolic and other usesThe apelin system is explored in metabolic, renal and lung disease.Pharmacology gapNative apelin-13 persists gray-market despite its short half-life.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

There is no approved consumer route. It exists mainly as a research compound; given the limited human data, self-experimentation is not advisable.

Gray-market and research-grade apelin-13 is moderately priced, and given its very short half-life the cost buys a poor-value research peptide rather than a usable therapy.

Not produced as an approved drug for this use; any consumer-facing material is research-use-only, typically synthesized overseas in China, with no quality assurance and frequently no certificate of analysis.

Research and gray-marketNative apelin-13 is sold as a reagent and gray-market peptide.Real development elsewhereAnalogs and small molecules are developed separately by pharma.No approved native formThere is no approved native-peptide product.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Apelin-13.

Nothing outstanding on this one.

Sources

The studies that matter

  • Cardiovascular and metabolic studies2000s-2010s

    Apelin improves cardiac output and insulin sensitivity in models, making the apelin-APJ axis a target for heart failure and metabolic disease.

  • Stroke neuroprotection (animal)2010s

    Intranasal apelin-13 reduced infarct size, limited neuronal death and promoted blood-vessel growth in mouse stroke models.

  • Human therapeuticsearly

    Apelin biology is being pursued for heart failure, but apelin-13 itself remains investigational, limited by very rapid breakdown.